Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date

References

• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2007176653255517507545
   PubMed Web of Science ®Google Scholar
• ChapmanKRManninoDMSorianoJBEpidemiology and costs of chronic obstructive pulmonary diseaseEur Respir J200627118820716387952
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med201318734736522878278
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of COPD2015 Available from: http://www.goldcopd.org/Accessed February 4, 2015
   Google Scholar
• CazzolaMBrusascoVCentanniSProject PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialistsPulm Pharmacol Ther20132621822823147424
   PubMed Web of Science ®Google Scholar
• van der MolenTCazzolaMBeyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrim Care Respir J20122110110822222945
   PubMedGoogle Scholar
• PalmqvistMIbsenTMellenALotvallJComparison of the relative efficacy of formoterol and salmeterol in asthmatic patientsAm J Respir Crit Care Med199916024424910390407
   PubMed Web of Science ®Google Scholar
• AalbersRAyresJBackerVFormoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trialEur Respir J200219593694312030736
   PubMed Web of Science ®Google Scholar
• GrossNJNelsonHSLapidusRJFormoterol Study GroupEfficacy and safety of formoterol fumarate delivered by nebulization to COPD patientsRespir Med2008102218919718363201
   PubMed Web of Science ®Google Scholar
• TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
   PubMed Web of Science ®Google Scholar
• NormanPLong-acting muscarinic M3 receptor antagonistsExpert Opin Ther Pat2006161315132020144059
   PubMed Web of Science ®Google Scholar
• PratMFernandezDBuilMADiscovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide)J Med Chem200952165076509219653626
   PubMed Web of Science ®Google Scholar
• MoultonBCFryerADMuscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPDBr J Pharmacol2011163445221198547
   PubMed Web of Science ®Google Scholar
• GavaldàAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• GavaldàAMiralpeixMRamosIAclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearanceEur Respir J200730Suppl 51209S210S
   Google Scholar
• GavaldàARamosICarcasonaCThe in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromidePulm Pharmacol Ther20142811412124928173
   PubMed Web of Science ®Google Scholar
• BeasleyRSinghSLokeYKEnrightPFurbergCDCall for worldwide withdrawal of tiotropium Respimat mist inhalerBMJ2012345e739023144209
   PubMed Web of Science ®Google Scholar
• GrasJGavaldàALlenasJThe preclinical cardiovascular safety profile of aclidinium bromide, a novel long-acting anticholinergic drugAm J Respir Crit Care Med2008177A654
   Google Scholar
• CazzolaMMateraMGNovel long-acting bronchodilators for COPD and asthmaBr J Pharmacol200815529129918604231
   PubMed Web of Science ®Google Scholar
• ChanezPBurgePSDahlRAclidinium bromide provides long-acting bronchodilation in patients with COPDPulm Pharmacol Ther201023152119683590
   PubMed Web of Science ®Google Scholar
• JoosGFSchelfhoutVJPauwelsRABronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patientsRespir Med201010486587220044242
   PubMed Web of Science ®Google Scholar
• SchelfhoutVJFerrerPJansatJMActivity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I studyBr J Clin Pharmacol201069545846420573081
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med201110558058721183326
   PubMed Web of Science ®Google Scholar
• SinghDMagnussenHKirstenAA randomized, placebo-and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patientsPulm Pharmacol Ther20122524825322497752
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J20124083083622441743
   PubMed Web of Science ®Google Scholar
• GelbAFTashkinDPMakeBJLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med20131071957196523916502
   PubMed Web of Science ®Google Scholar
• BeierJKirstenAMMrózREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb studyCOPD20131051152223819698
   PubMedGoogle Scholar
• RottenkolberMRottenkolberDFischerRInhaled beta-2 agonists/muscarinic antagonists and acute myocardial infarction in COPD patientsRespir Med20141081075109024950946
   PubMed Web of Science ®Google Scholar
• CortijoJMataMMilaraJAclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airwaysEur Respir J201137224425420525722
   PubMed Web of Science ®Google Scholar
• CaramoriGCasolariPDi GregorioCMUC5AC expression is increased in bronchial submucosal glands of stable COPD patientsHistopathology200955332133119723147
   PubMed Web of Science ®Google Scholar
• InnesALWoodruffPGFerrandoREEpithelial mucin stores are increased in the large airways of smokers with airflow obstructionChest200613041102110817035444
   PubMed Web of Science ®Google Scholar
• DameraGJiangMZhaoHAclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammationEur J Pharmacol20106491–334935320868661
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFACCORD I study investigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res20111215521518460
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPMateraMGAclidinium bromide/formoterol fumerate fixed-dose combination for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother201314677578123472632
   PubMed Web of Science ®Google Scholar
• SliwinskiPPerngD-WChuchalinAJonesPWEfficacy and safety of once-daily aclidinium bromide 200 μg in combination with formoterol in patients with COPDThorax201065A136
   Web of Science ®Google Scholar
• MagnussenHWatzHKretschmarGPharmakokinetik, Sicherheit und Aktivitat von formoterol verabreicht uber den Genuair Inhalator® mit und ohne Aclidinium-BromidPneumologie201165V446 German
   Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD Study InvestigatorsEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res201415112325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiARoglianiPComparative effectiveness of drugs for chronic obstructive pulmonary diseaseDrugs Today2012481278579423243635
   PubMed Web of Science ®Google Scholar
• SalamaROYoungPMRoguedaPAdvances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?Expert Opin Pharmacother2011121913193221714776
   PubMed Web of Science ®Google Scholar
• MoenMDIndacaterol: in chronic obstructive pulmonary diseaseDrugs2010702269228021080743
   PubMed Web of Science ®Google Scholar
• van NoordJAKorduckiLHamiltonAKokerPFour weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract]Am J Respir Crit Care Med2009179A6183
   Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWDose-related efficacy of vilanterol trifenatate (VI) in COPD [abstract]Eur Respir J201036Suppl 54217s
   Google Scholar
• VestboJVogelmeierCCreemersJFalquesMRiberaAGarcia GilEOnset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPDCOPD2010733133620854047
   PubMedGoogle Scholar
• VerkindreCFukuchiYFlémaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med20101041482148920541381
   PubMed Web of Science ®Google Scholar
• KerwinEMHebertJPedinoffANVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [abstract]Am J Respir Crit Care Med2012185A2920
   Google Scholar
• BatemanEFeldmanGKilbrideSEfficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPDClin Respir J2012624825722329914
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDJrDonohueJFSerbyCWMenjogeSSWitekTJJrfor the US Tiotropium Study GroupThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trialChest20001181294130211083677
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• BeierJvan NoordJDeansASafety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patientsInt J Chron Obstruct Pulmon Dis2012715316422419863
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med200910351652419208459
   PubMed Web of Science ®Google Scholar
• HananiaNABootaAKerwinETomlinsonLDenis-MizeKEfficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trialDrugs2009691205121619537837
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD20096172519229704
   PubMedGoogle Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med20081021511152018804362
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJ-LJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med2010104995100420303247
   PubMed Web of Science ®Google Scholar
• ReisnerCFogartyCSpangenthalSNovel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]Am J Respir Crit Care Med2011183A6453
   Web of Science ®Google Scholar
• ReisnerCSt RoseEStromSFixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]Eur Respir J201138Suppl 55150s
   Google Scholar
• van NoordJABuhlRLaForceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax2010651086109120978028
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patientsCOPD2010741842721166630
   PubMedGoogle Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRudolfMQVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: the ENLIGHTEN study [abstract]Eur Respir J201240Suppl 56P2896
   Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]Eur Respir J201036Suppl 541014s
   Google Scholar
• AalbersRMaleki-YazdiMRHamiltonADose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPDEur Respir J201240Suppl 56525s
   Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterGSafety and tolerability of the GSK573719/vilanterol combination in patients with COPD [abstract]Am J Respir Crit Care Med2012185A2938
   Google Scholar